WCN24-2370 Effect of initiation and rapid maximisation of RAASi in patients with CKD and heart failure with reduced ejection fraction – observations from the LIFT study, an ongoing trial

The use of renin-angiotensin-aldosterone inhibitors (RAASi) in heart failure patients reduces hospital admissions and mortality; however, this is limited in CKD patients by hyperkalaemia, and concerns of worsening renal function. Novel potassium binders like Lokelma (sodium zirconium cyclosilicate – SZC) can potentially allow clinicians to achieve optimal dosing of RAASi. The LIFT study (Lokelma for maximization of RAASi in patients with CKD and HF) is a phase III, randomised controlled trial to evaluate the effect of Lokelma in allowing initiation and maximization of RAASi in patients with CKD and HF with reduced ejection fraction on nil or suboptimal RAASi.